Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Persimmon says trading 'well' year-to-date

(Sharecast News) - Persimmon reported in line trading for the year-to-date with its rate of private sales and selling prices having risen. Its network of outlets meanwhile continued to grow, the company said in an update, for the year to 27 April, published ahead of its AGM.

Chief executive officer Dean Finch added that recent geopolitical uncertainty had not yet had an immediate impact on the business, nor on consumer confidence.

He also reiterated guidance for full-year completions of between 11,000-11,5000 - should the UK housing market stay stable.

Net private sales per outlet, per week, rose 1.0% from the same period of 2024 to 0.74, forward sales were up by 12% to £2.34bn.

The number of outlets meanwhile increased 5% to 275 and its land holdings by 2% to approximately 83,000.

For Aarin Chiekrie at Hargreaves Lansdown, the positive sales momentum helped profits "continue their growth after two prior years of declines".

As well, the analyst noted Persimmon's in-house materials business, labelling it a "key differentiator" that gave it quicker and less expensive access to key materials, allowing it to same about £5,500 per plot.

Its houses are also usually priced more than 20% beneath the newbuild national average, so its sales tended to be more resilient when faced with uncertainty, Chiekrie said.

"With shareholder payouts a key focus and Persimmon's valuation sitting some way below the long-term average, this could mark an opportunity for long-term investors."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.